# PT-141 FAQ: Bremelanotide Questions, Answered From the Research > PT-141 questions answered from the published record — what it is, how it works, the dosage, whether it's FDA-approved, and what the trials showed. Cited where quantitative. Direct answers about PT-141 (bremelanotide) from the published literature and the approved label — definitional, mechanistic, dosing, and efficacy. ## Does PT-141 work? In two Phase 3 RCTs (RECONNECT) in premenopausal women with HSDD, bremelanotide `1.75 mg` subcutaneous as-needed met both coprimary endpoints with statistically significant but clinically modest improvements in desire and desire-related distress [3]. Benefit outside that approved population is not established. Independent re-analyses argue the effect, while real, is small [3]. ## What were the results of the PT-141 clinical trials? The RECONNECT trials (`n=1267`) showed integrated FSFI-desire `+0.35` (`P<.001`) and FSDS-DAO item 13 `-0.33` (`P<.001`) versus placebo over 24 weeks [3]. A 52-week open-label extension (684 women) sustained the effect with no new safety signals [4]. Both coprimary endpoints were met in both trials [3]. ## What are the benefits of PT-141? In the approved indication, the documented benefit is a modest increase in sexual desire and a reduction in distress about low desire in premenopausal women with HSDD [3][4]. The magnitude has been debated as small in critical re-analyses [3]. No benefit is established in men, after menopause, or for sexual performance. ## How big is the effect of bremelanotide on sexual desire? Integrated trial effects were `+0.35` on the FSFI desire domain and `-0.33` on FSDS-DAO item 13 versus placebo [3]. Independent re-analyses (Spielmans 2021, 2024) argue these effects, while statistically significant, are small and of debatable clinical meaningfulness [3]. Both the significance and the modest size are real. ## What is PT-141? PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin receptors (MC3R/MC4R) [1][6]. As bremelanotide it is FDA-approved (NDA `210557`, 2019) for HSDD in premenopausal women [6]. ## What is PT-141 peptide? It is a seven-amino-acid cyclic peptide, `Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH`, related to melanotan II [6]. It acts on melanocortin receptors in the brain rather than on blood vessels, which distinguishes it from the PDE-5 inhibitor class [1]. ## What does the PT-141 peptide do? It stimulates MC4R (and MC3R) in hypothalamic and limbic circuits, engaging dopaminergic pathways linked to sexual motivation [1]. In the approved use it raises sexual desire in premenopausal women with HSDD [3]. A 2022 fMRI study showed it altering brain processing of sexual cues [13]. ## What is PT-141 used for? As bremelanotide it is approved only for acquired, generalized HSDD in premenopausal women [6]. Uses in men, for erectile dysfunction, or in postmenopausal women are off-label and supported only by early-phase or investigational evidence [1][6]. ## Is PT-141 the same as bremelanotide? Yes. PT-141 is the development/research code; bremelanotide is the international nonproprietary name (INN) for the same molecule [6]. It was approved under NDA `210557` in June 2019 [6]. The research-chemical label and the approved drug name refer to the same compound, but not the same regulated product. ## What is bremelanotide? Bremelanotide is the approved melanocortin receptor agonist — the INN for PT-141 — administered as a `1.75 mg` subcutaneous injection as needed for HSDD in premenopausal women [5][6]. It received its first regulatory approval in the United States in June 2019 [6]. ## How does PT-141 work? It activates central melanocortin receptors, chiefly MC4R, in hypothalamic circuits such as the medial preoptic area, engaging dopamine signaling tied to sexual desire [1]. Unlike PDE-5 inhibitors it acts on the brain, not on vascular blood flow [1]. A 2022 fMRI study confirmed central effects in women with HSDD [13]. ## What receptors does PT-141 act on? Primarily the melanocortin 4 receptor (MC4R), with secondary activity at MC3R [6]. Peripheral MC1R activation explains the hyperpigmentation seen with repeated frequent dosing [5]. MC4R's presence in appetite circuits also accounts for the caloric-intake effects in high-frequency dosing [4][6]. ## Does PT-141 work through the brain or through blood flow? Through the brain. It is a central melanocortin agonist acting on neural circuits of sexual motivation, mechanistically distinct from PDE-5 inhibitors that act peripherally on vascular smooth muscle [1]. A 2022 fMRI study showed measurable changes in central brain processing of sexual stimuli [13]. ## What is a melanocortin receptor agonist? A compound that activates the melanocortin receptor family (MC1R-MC5R) [1]. PT-141 targets the central MC3R/MC4R subtypes that modulate sexual desire and appetite [6]. It is a synthetic analogue of the body's own alpha-MSH, the natural ligand for these receptors [1]. ## Does PT-141 increase testosterone? No. PT-141 does not act via the HPG axis and does not directly raise testosterone [5]. It works on central melanocortin receptors — a different system entirely — which is a common point of confusion for a compound discussed in a sexual-function context [5]. ## How is PT-141 different from PDE-5 inhibitors? PDE-5 inhibitors (such as sildenafil) act peripherally on penile vascular smooth muscle to improve blood flow; PT-141 acts centrally on brain melanocortin receptors governing sexual motivation [1]. They address different mechanisms — vascular versus neural — and PT-141 is approved for desire in women, not erectile blood flow. ## What is the PT-141 dosage? In the approved label, bremelanotide is `1.75 mg` subcutaneously as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than eight per month [5]. Reported as a label finding, not a protocol for any reader. ## How much PT-141 should I take? This site does not recommend a dose. The studied/approved figure is `1.75 mg` subcutaneous as-needed in premenopausal women with HSDD [5]; Phase 2 explored `0.75`, `1.25`, and `1.75 mg` [8]. Material sold as research chemical is for laboratory use only [5]. ## How much PT-141 to inject? The approved subcutaneous dose studied in the RECONNECT program was `1.75 mg` as needed [3][5]. This is reported as a trial/label finding, not as dosing guidance. The approved product is a ready-to-use subcutaneous autoinjector at that fixed dose [5]. ## How do you reconstitute PT-141? The approved bremelanotide product is supplied as a ready-to-use subcutaneous autoinjector, not a powder requiring reconstitution [5]. The approved route in the trials and the label is subcutaneous [3][5]. Laboratory research material is a separate, unregulated product and is not the approved finished drug. ## How do you take PT-141? In the approved indication it is given by subcutaneous injection as needed before anticipated sexual activity, at least 45 minutes prior [5]. Early intranasal formulations were discontinued for pharmacokinetic variability [5]. This describes the labeled route, not a recommendation to administer it. ## How often can you take PT-141? The label limits dosing to no more than one `1.75 mg` dose per 24 hours and no more than eight doses per month [5]. This frequency cap is reported as a label finding; the cap is also relevant to the hyperpigmentation seen with frequent repeated dosing [5]. --- A documentation-grade reading of the bremelanotide record — the approved label and the Phase 3 endpoints logged to source, the effect-size debate left in plain view, and the field reports fenced off from the evidence; not a clinic, not a vendor, not a prescription.